A randomised, double-blind, placebo-controlled, multicentre clinical trial of AZD1656 in diabetic patients hospitalised with COVID-19: The ARCADIA Trial - implications for therapeutic immune modulation
The Lancet,
BackgroundA potential immunotherapeutic role for AZD656 (a glucokinase activator) in the treatment of COVID-9 was hypothesized.